PDF herunterladen
Semin intervent Radiol 2018; 35(03): 165-168
DOI: 10.1055/s-0038-1661347
Review Article
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Transjugular Intrahepatic Portosystemic Shunt Placement for Refractory Ascites: Review and Update of the Literature

Ana Cecilia Burgos
1   Northwestern University, Feinberg School of Medicine, Chicago, Illinois
,
Bartley Thornburg
2   Department of Radiology, Section of Interventional Radiology, Northwestern Memorial Hospital, Chicago, Illinois
› Institutsangaben
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
06. August 2018 (online)

Auch verfügbar auf
    Lizenzen und Reprints

Abstract

Ascites is the most common complication of cirrhosis, impairs quality of life, and carries a poor prognosis. Transjugular intrahepatic portosystemic shunt (TIPS) is a well-validated therapy for refractory ascites and is superior at reducing the accumulation of fluid compared with paracentesis. More recent evidence has shown that TIPS also provides an improved transplant-free survival compared with paracentesis. To maximize the clinical efficacy and survival advantage, proper patient selection is crucial. While current guidelines recommend that elective TIPS for ascites should be performed only in patients with MELD ≤ 18, recent literature suggests that elective TIPS safely and effectively controls ascites and potentially provides a survival advantage in patients with higher MELD scores (≤ 24). The evolution of these findings likely represents the combination of improved medical management of cirrhotic patients, improved devices, and a better knowledge of selection criteria for potential TIPS patients. This article will review the pathophysiology and management of ascites, with a focus on the evidence supporting TIPS placement for refractory ascites.

Keywords

TIPS - portal hypertension - refractory ascites
 

  • References

  • 1 Ginés P, Quintero E, Arroyo V. , et al. Compensated cirrhosis: natural history and prognostic factors. Hepatology 1987; 7 (01) 122-128
    CrossrefPubMedGoogle Scholar
  • 2 Salerno F, Cammà C, Enea M, Rössle M, Wong F. Transjugular intrahepatic portosystemic shunt for refractory ascites: a meta-analysis of individual patient data. Gastroenterology 2007; 133 (03) 825-834
    CrossrefPubMedGoogle Scholar
  • 3 Ginès P, Fernández-Esparrach G, Arroyo V. Ascites and renal functional abnormalities in cirrhosis. Pathogenesis and treatment. Baillieres Clin Gastroenterol 1997; 11 (02) 365-385
    CrossrefPubMedGoogle Scholar
  • 4 Morali GA, Sniderman KW, Deitel KM. , et al. Is sinusoidal portal hypertension a necessary factor for the development of hepatic ascites?. J Hepatol 1992; 16 (1-2): 249-250
    CrossrefPubMedGoogle Scholar
  • 5 Salerno F, Guevara M, Bernardi M. , et al. Refractory ascites: pathogenesis, definition and therapy of a severe complication in patients with cirrhosis. Liver Int 2010; 30 (07) 937-947
    CrossrefPubMedGoogle Scholar
  • 6 European Association for the Study of the Liver. EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis. J Hepatol 2010; 53 (03) 397-417
    CrossrefPubMedGoogle Scholar
  • 7 Fogel MR, Sawhney VK, Neal EA, Miller RG, Knauer CM, Gregory PB. Diuresis in the ascitic patient: a randomized controlled trial of three regimens. J Clin Gastroenterol 1981; 3 (Suppl. 01) 73-80
    PubMedGoogle Scholar
  • 8 Moore KP, Wong F, Gines P. , et al. The management of ascites in cirrhosis: report on the consensus conference of the International Ascites Club. Hepatology 2003; 38 (01) 258-266
    CrossrefPubMedGoogle Scholar
  • 9 Arroyo V, Ginès P, Gerbes AL. , et al. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. International Ascites Club. Hepatology 1996; 23 (01) 164-176
    CrossrefPubMedGoogle Scholar
  • 10 Piano S, Tonon M, Angeli P. Management of ascites and hepatorenal syndrome. Hepatol Int 2018; 12 (Suppl. 01) 122-134
    CrossrefPubMedGoogle Scholar
  • 11 Bories P, Garcia Compean D, Michel H. , et al. The treatment of refractory ascites by the LeVeen shunt. A multi-centre controlled trial (57 patients). J Hepatol 1986; 3 (02) 212-218
    CrossrefPubMedGoogle Scholar
  • 12 Runyon BA. ; AASLD. Introduction to the revised American Association for the Study of Liver Diseases Practice Guideline management of adult patients with ascites due to cirrhosis 2012. Hepatology 2013; 57 (04) 1651-1653
    CrossrefPubMedGoogle Scholar
  • 13 Zhao R, Lu J, Shi Y, Zhao H, Xu K, Sheng J. Current management of refractory ascites in patients with cirrhosis. J Int Med Res 2018; 46 (03) 1138-1145
    CrossrefPubMedGoogle Scholar
  • 14 Bai M, Qi XS, Yang ZP, Yang M, Fan DM, Han GH. TIPS improves liver transplantation-free survival in cirrhotic patients with refractory ascites: an updated meta-analysis. World J Gastroenterol 2014; 20 (10) 2704-2714
    CrossrefPubMedGoogle Scholar
  • 15 Saab S, Nieto JM, Lewis SK, Runyon BA. TIPS versus paracentesis for cirrhotic patients with refractory ascites. Cochrane Database Syst Rev 2006; (04) CD004889
    PubMedGoogle Scholar
  • 16 D'Amico G, Luca A, Morabito A, Miraglia R, D'Amico M. Uncovered transjugular intrahepatic portosystemic shunt for refractory ascites: a meta-analysis. Gastroenterology 2005; 129 (04) 1282-1293
    CrossrefPubMedGoogle Scholar
  • 17 Bureau C, Garcia Pagan JC, Layrargues GP. , et al. Patency of stents covered with polytetrafluoroethylene in patients treated by transjugular intrahepatic portosystemic shunts: long-term results of a randomized multicentre study. Liver Int 2007; 27 (06) 742-747
    CrossrefPubMedGoogle Scholar
  • 18 Bureau C, Garcia-Pagan JC, Otal P. , et al. Improved clinical outcome using polytetrafluoroethylene-coated stents for TIPS: results of a randomized study. Gastroenterology 2004; 126 (02) 469-475
    CrossrefPubMedGoogle Scholar
  • 19 Perarnau JM, Le Gouge A, Nicolas C. , et al; STIC-TIPS Group. Covered vs. uncovered stents for transjugular intrahepatic portosystemic shunt: a randomized controlled trial. J Hepatol 2014; 60 (05) 962-968
    CrossrefPubMedGoogle Scholar
  • 20 Triantafyllou T, Aggarwal P, Gupta E, Svetanoff WJ, Bhirud DP, Singhal S. Polytetrafluoroethylene-covered stent graft versus bare stent in transjugular intrahepatic portosystemic shunt: systematic review and meta-analysis. J Laparoendosc Adv Surg Tech A 2018
    PubMedGoogle Scholar
  • 21 Bureau C, Thabut D, Oberti F. , et al. Transjugular intrahepatic portosystemic shunts with covered stents increase transplant-free survival of patients with cirrhosis and recurrent ascites. Gastroenterology 2017; 152 (01) 157-163
    CrossrefPubMedGoogle Scholar
  • 22 Albillos A, Bañares R, González M, Catalina MV, Molinero LM. A meta-analysis of transjugular intrahepatic portosystemic shunt versus paracentesis for refractory ascites. J Hepatol 2005; 43 (06) 990-996
    CrossrefPubMedGoogle Scholar
  • 23 Narahara Y, Kanazawa H, Fukuda T. , et al. Transjugular intrahepatic portosystemic shunt versus paracentesis plus albumin in patients with refractory ascites who have good hepatic and renal function: a prospective randomized trial. J Gastroenterol 2011; 46 (01) 78-85
    CrossrefPubMedGoogle Scholar
  • 24 Malinchoc M, Kamath PS, Gordon FD, Peine CJ, Rank J, ter Borg PC. A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts. Hepatology 2000; 31 (04) 864-871
    CrossrefPubMedGoogle Scholar
  • 25 Kamath PS, Wiesner RH, Malinchoc M. , et al. A model to predict survival in patients with end-stage liver disease. Hepatology 2001; 33 (02) 464-470
    CrossrefPubMedGoogle Scholar
  • 26 Salerno F, Merli M, Cazzaniga M. , et al. MELD score is better than Child-Pugh score in predicting 3-month survival of patients undergoing transjugular intrahepatic portosystemic shunt. J Hepatol 2002; 36 (04) 494-500
    CrossrefPubMedGoogle Scholar
  • 27 Schepke M, Roth F, Fimmers R. , et al. Comparison of MELD, Child-Pugh, and Emory model for the prediction of survival in patients undergoing transjugular intrahepatic portosystemic shunting. Am J Gastroenterol 2003; 98 (05) 1167-1174
    CrossrefPubMedGoogle Scholar
  • 28 Ferral H, Gamboa P, Postoak DW. , et al. Survival after elective transjugular intrahepatic portosystemic shunt creation: prediction with model for end-stage liver disease score. Radiology 2004; 231 (01) 231-236
    CrossrefPubMedGoogle Scholar
  • 29 Boyer TD, Haskal ZJ. ; American Association for the Study of Liver Diseases. The role of transjugular intrahepatic portosystemic shunt (TIPS) in the management of portal hypertension: update 2009. Hepatology 2010; 51 (01) 306
    CrossrefPubMedGoogle Scholar
  • 30 Montgomery A, Ferral H, Vasan R, Postoak DW. MELD score as a predictor of early death in patients undergoing elective transjugular intrahepatic portosystemic shunt (TIPS) procedures. Cardiovasc Intervent Radiol 2005; 28 (03) 307-312
    CrossrefPubMedGoogle Scholar
  • 31 Ascha M, Hanouneh M, , S Ascha M. , et al. Transjugular intrahepatic porto-systemic shunt in patients with liver cirrhosis and model for end-stage liver disease ≥15. Dig Dis Sci 2017; 62 (02) 534-542
    CrossrefPubMedGoogle Scholar
  • 32 Spengler EK, Hunsicker LG, Zarei S, Zimmerman MB, Voigt MD. Transjugular intrahepatic portosystemic shunt does not independently increase risk of death in high model for end stage liver disease patients. Hepatol Commun 2017; 1 (05) 460-468
    CrossrefPubMedGoogle Scholar
  • 33 Unger LW, Berlakovich GA, Trauner M, Reiberger T. Management of portal hypertension before and after liver transplantation. Liver Transpl 2018; 24 (01) 112-121
    CrossrefPubMedGoogle Scholar
  • 34 Feyssa E, Ortiz J, Grewal K. , et al. MELD score less than 15 predicts prolonged survival after transjugular intrahepatic portosystemic shunt for refractory ascites after liver transplantation. Transplantation 2011; 91 (07) 786-792
    PubMedGoogle Scholar
  • 35 Kim JJ, Dasika NL, Yu E, Fontana RJ. Transjugular intrahepatic portosystemic shunts in liver transplant recipients. Liver Int 2008; 28 (02) 240-248
    CrossrefPubMedGoogle Scholar
  • 36 Saad WE, Darwish WM, Davies MG. , et al. Transjugular intrahepatic portosystemic shunts in liver transplant recipients: technical analysis and clinical outcome. AJR Am J Roentgenol 2013; 200 (01) 210-218
    CrossrefPubMedGoogle Scholar
  • 37 Chen B, Wang W, Tam MD, Quintini C, Fung JJ, Li X. Transjugular intrahepatic portosystemic shunt in liver transplant recipients: indications, feasibility, and outcomes. Hepatol Int 2015; 9 (03) 391-398
    CrossrefPubMedGoogle Scholar
  • 38 King A, Masterton G, Gunson B. , et al. A case-controlled study of the safety and efficacy of transjugular intrahepatic portosystemic shunts after liver transplantation. Liver Transpl 2011; 17 (07) 771-778
    CrossrefPubMedGoogle Scholar